Annette Langer-Gould1, Jessica B Smith2, Kathleen B Albers2, Anny H Xiang2, Jun Wu2, Erica H Kerezsi2, Keeli McClearnen2, Edlin G Gonzales2, Amethyst D Leimpeter2, Stephen K Van Den Eeden2. 1. From the Department of Neurology (A.L.-G.), Southern California Permanente Medical Group, Los Angeles Medical Center; Department of Research & Evaluation (J.B.S., A.H.X., J.W., E.G.G.), Kaiser Permanente Southern California; and Division of Research (K.B.A., E.H.K., K.M., A.D.L., S.K.V.D.E.), Kaiser Permanente Northern California, Los Angeles, CA. Annette.M.Langer-Gould@kp.org. 2. From the Department of Neurology (A.L.-G.), Southern California Permanente Medical Group, Los Angeles Medical Center; Department of Research & Evaluation (J.B.S., A.H.X., J.W., E.G.G.), Kaiser Permanente Southern California; and Division of Research (K.B.A., E.H.K., K.M., A.D.L., S.K.V.D.E.), Kaiser Permanente Northern California, Los Angeles, CA.
Abstract
OBJECTIVE: To determine whether women with multiple sclerosis (MS) diagnosed according to current criteria are at an increased risk of postpartum relapses and to assess whether this risk is modified by breastfeeding or MS disease-modifying therapies (DMTs), we examined the electronic health records (EHRs) of 466 pregnancies among 375 women with MS and their infants. METHODS: We used prospectively collected information from the EHR at Kaiser Permanente Southern and Northern California between 2008 and 2016 of the mother and infant to identify treatment history, breastfeeding, and relapses. Multivariable models accounting for measures of disease severity were used. RESULTS: In the postpartum year, 26.4% relapsed, 87% breastfed, 36% breastfed exclusively for at least 2 months, and 58.8% did not use DMTs. At pregnancy onset, 67.2% had suboptimally controlled disease. Annualized relapse rates (ARRs) declined from 0.37 before pregnancy to 0.14-0.07 (p < 0.0001) during pregnancy, but in the postpartum period, we did not observe any rebound disease activity. The ARR was 0.27 in the first 3 months postpartum, returning to prepregnancy rates at 4-6 months (0.37). Exclusive breastfeeding reduced the risk of early postpartum relapses (adjusted hazard ratio = 0.37, p = 0.009), measures of disease severity increased the risk, and resuming modestly effective DMTs had no effect (time-dependent covariate, p = 0.62). CONCLUSION: Most women diagnosed with MS today can have children without incurring an increased risk of relapses. Women with suboptimal disease control before pregnancy may benefit from highly effective DMTs that are compatible with pregnancy and lactation. Women with MS should be encouraged to breastfeed exclusively.
OBJECTIVE: To determine whether women with multiple sclerosis (MS) diagnosed according to current criteria are at an increased risk of postpartum relapses and to assess whether this risk is modified by breastfeeding or MS disease-modifying therapies (DMTs), we examined the electronic health records (EHRs) of 466 pregnancies among 375 women with MS and their infants. METHODS: We used prospectively collected information from the EHR at Kaiser Permanente Southern and Northern California between 2008 and 2016 of the mother and infant to identify treatment history, breastfeeding, and relapses. Multivariable models accounting for measures of disease severity were used. RESULTS: In the postpartum year, 26.4% relapsed, 87% breastfed, 36% breastfed exclusively for at least 2 months, and 58.8% did not use DMTs. At pregnancy onset, 67.2% had suboptimally controlled disease. Annualized relapse rates (ARRs) declined from 0.37 before pregnancy to 0.14-0.07 (p < 0.0001) during pregnancy, but in the postpartum period, we did not observe any rebound disease activity. The ARR was 0.27 in the first 3 months postpartum, returning to prepregnancy rates at 4-6 months (0.37). Exclusive breastfeeding reduced the risk of early postpartum relapses (adjusted hazard ratio = 0.37, p = 0.009), measures of disease severity increased the risk, and resuming modestly effective DMTs had no effect (time-dependent covariate, p = 0.62). CONCLUSION: Most women diagnosed with MS today can have children without incurring an increased risk of relapses. Women with suboptimal disease control before pregnancy may benefit from highly effective DMTs that are compatible with pregnancy and lactation. Women with MS should be encouraged to breastfeed exclusively.
Authors: Annette Langer-Gould; Rita A Popat; Stella M Huang; Kristin Cobb; Paulo Fontoura; Michael K Gould; Lorene M Nelson Journal: Arch Neurol Date: 2006-12
Authors: Emilio Portaccio; Angelo Ghezzi; Bahia Hakiki; Andrea Sturchio; Vittorio Martinelli; Lucia Moiola; Francesco Patti; Gian Luigi Mancardi; Claudio Solaro; Maria Rosaria Tola; Carlo Pozzilli; Laura De Giglio; Rocco Totaro; Alessandra Lugaresi; Giovanna De Luca; Damiano Paolicelli; Maria Giovanna Marrosu; Giancarlo Comi; Maria Trojano; Maria Pia Amato Journal: J Neurol Neurosurg Psychiatry Date: 2014-01-08 Impact factor: 10.154
Authors: Ralf Gold; Ludwig Kappos; Douglas L Arnold; Amit Bar-Or; Gavin Giovannoni; Krzysztof Selmaj; Carlo Tornatore; Marianne T Sweetser; Minhua Yang; Sarah I Sheikh; Katherine T Dawson Journal: N Engl J Med Date: 2012-09-20 Impact factor: 91.245
Authors: Cesar G Victora; Rajiv Bahl; Aluísio J D Barros; Giovanny V A França; Susan Horton; Julia Krasevec; Simon Murch; Mari Jeeva Sankar; Neff Walker; Nigel C Rollins Journal: Lancet Date: 2016-01-30 Impact factor: 79.321
Authors: Edward J D Webb; David Meads; Ieva Eskytė; Helen L Ford; Hilary L Bekker; Jeremy Chataway; George Pepper; Joachim Marti; Yasmina Okan; Sue H Pavitt; Klaus Schmierer; Ana Manzano Journal: Patient Date: 2020-10 Impact factor: 3.883
Authors: Wei Zhen Yeh; Putu Ayu Widyastuti; Anneke Van der Walt; Jim Stankovich; Eva Havrdova; Dana Horakova; Karolina Vodehnalova; Serkan Ozakbas; Sara Eichau; Pierre Duquette; Tomas Kalincik; Francesco Patti; Cavit Boz; Murat Terzi; Bassem I Yamout; Jeannette Lechner-Scott; Patrizia Sola; Olga G Skibina; Michael Barnett; Marco Onofrj; Maria José Sá; Pamela Ann McCombe; Pierre Grammond; Radek Ampapa; Francois Grand'Maison; Roberto Bergamaschi; Daniele L A Spitaleri; Vincent Van Pesch; Elisabetta Cartechini; Suzanne Hodgkinson; Aysun Soysal; Albert Saiz; Melissa Gresle; Tomas Uher; Davide Maimone; Recai Turkoglu; Raymond Mm Hupperts; Maria Pia Amato; Franco Granella; Celia Oreja-Guevara; Ayse Altintas; Richard A Macdonell; Tamara Castillo-Trivino; Helmut Butzkueven; Raed Alroughani; Vilija G Jokubaitis Journal: Neurology Date: 2021-04-20 Impact factor: 9.910
Authors: Annika Anderson; Kristen M Krysko; Alice Rutatangwa; Tanya Krishnakumar; Chelsea Chen; William Rowles; Chao Zhao; Maria K Houtchens; Riley Bove Journal: Neurol Neuroimmunol Neuroinflamm Date: 2021-02-19